Sectors

PROK
ProKidney Corp.
1.56
14 x 1.55
62 x 1.56
bid
ask
-
0.03
2.18%
12:28 PM
timesize
Ytd-30.35%
1y-48.85%
1.55
day range
1.61
1.52
52 week range
3.55
Open1.59Prev Close1.59Low1.55High1.61Mkt Cap536.32M
Vol169.99KAvg Vol1.12MEPS-0.53P/E-3.01Forward P/E-5.33
Beta1.61Short Ratio3.72Inst. Own30.44%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1250-d Avg1.75200-d Avg2.161yr Est5.83

PROK News

AEVEX, Abivax, Watts Water Technologies And Other Big Stocks Moving Higher On Tuesday
benzinga.com
AEVEX, Abivax, Watts Water Technologies And Other Big Stocks Moving Higher On Tuesday

Stocks up, Dow Jones +100 points. AEVEX Corp shares rose 11.8% on $50m Air Force contract. Other big

Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
benzinga.com
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol

ProKidney Appoints Kenneth Locke as Chief Technical Officer
globenewswire.com
ProKidney Appoints Kenneth Locke as Chief Technical Officer

Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Che

benzinga.com
HC Wainwright & Co. Reiterates Buy on ProKidney, Maintains $12 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates ProKidney (NASDAQ:PROK) with a Buy an

ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
zacks.com
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates

ProKidney Corp. (PROK) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus

benzinga.com
ProKidney Q1 EPS $(0.14), Inline, Sales $226.000K Beat $143.667K Estimate

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which met the analyst consens

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
globenewswire.com
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

WINSTON-SALEM, N.C., May 15, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or

Head-To-Head Contrast: ProKidney (NASDAQ:PROK) & Phio Pharmaceuticals (NASDAQ:PHIO)
defenseworld.net
Head-To-Head Contrast: ProKidney (NASDAQ:PROK) & Phio Pharmaceuticals (NASDAQ:PHIO)

Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report)

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
globenewswire.com
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Office

WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”

ProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of “Moderate Buy” by Brokerages
defenseworld.net
ProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of ProKidney Corp. (NASDAQ: PROK - Get Free Report) have earned a consensus rating of "Modera

benzinga.com
ProKidney Q4 EPS $(0.14) Misses $(0.11) Estimate, Sales $225.000K Beat $83.333K Estimate

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which missed the analyst cons

ProKidney (PROK) Projected to Post Earnings on Monday
defenseworld.net
ProKidney (PROK) Projected to Post Earnings on Monday

ProKidney (NASDAQ: PROK - Get Free Report) will likely be releasing its Q4 2025 results before the m

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably
seekingalpha.com
ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably

PROK's main value driver is Rilparencel, which is now in a pivotal trial called PROACT 1. The FDA al

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
seekingalpha.com
ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
benzinga.com
This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

benzinga.com
HC Wainwright & Co. Initiates Coverage On ProKidney with Buy Rating, Announces Price Target of $12

HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on ProKidney (NASDAQ:PROK) wi

10 Health Care Stocks With Whale Alerts In Today's Session
benzinga.com
10 Health Care Stocks With Whale Alerts In Today's Session

ProKidney Corp. (NASDAQ:PROK) Receives Average Rating of “Hold” from Analysts
defenseworld.net
ProKidney Corp. (NASDAQ:PROK) Receives Average Rating of “Hold” from Analysts

Shares of ProKidney Corp. (NASDAQ: PROK - Get Free Report) have been given a consensus recommendatio

benzinga.com
ProKidney Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $217.000K Beat $44.250K Estimate

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.12) per share which beat the analyst consen

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
globenewswire.com
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

WINSTON-SALEM, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
globenewswire.com
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Soci

WINSTON-SALEM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o

Head-To-Head Review: Tonix Pharmaceuticals (NASDAQ:TNXP) versus ProKidney (NASDAQ:PROK)
defenseworld.net
Head-To-Head Review: Tonix Pharmaceuticals (NASDAQ:TNXP) versus ProKidney (NASDAQ:PROK)

Tonix Pharmaceuticals (NASDAQ: TNXP - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference
globenewswire.com
ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference an

WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025
globenewswire.com
ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's

WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” o

SPAC King Chamath Palihapitiya Tells Retail Investors To Stay Away From His New SPAC
benzinga.com
SPAC King Chamath Palihapitiya Tells Retail Investors To Stay Away From His New SPAC

Chamath Palihapitiya is back with another SPAC. This time he's telling retail investors to stay

ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy
seekingalpha.com
ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy

I rate ProKidney a buy due to promising Phase 2 data for rilparencel in advanced CKD, strong FDA ali

ProKidney Corp. (PROK) Presents At Citi's Biopharma Back To School Conference Transcript
seekingalpha.com
ProKidney Corp. (PROK) Presents At Citi's Biopharma Back To School Conference Transcript

ProKidney Corp. (NASDAQ:PROK ) Citi's Biopharma Back to School Conference September 3, 2025 10:30 AM

Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
benzinga.com
Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  During the session on Thursday, 461 stocks hit new 52-week lows.